Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials

<strong>Background</strong> The net absolute effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors across different patient groups have not been quantified. <br> <strong>Methods</strong> We performed a meta-analysis of published large (>500 participants/arm)...

書誌詳細
主要な著者:	Staplin, N, Roddick, AJ, Emberson, J, Reith, C, Riding, A, Wonnacott, A, Kuverji, A, Bhandari, S, Baigent, C, Haynes, R, Herrington, WG
フォーマット:	Journal article
言語:	English
出版事項:	Elsevier 2021

類似資料

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
著者:: Natalie Staplin, PhD, 等
出版事項: (2021-11-01)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
著者:: Herrington, W, 等
出版事項: (2022)

UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (sglt-2) inhibition in adults with kidney disease 2023 update
著者:: Roddick, AJ, 等
出版事項: (2023)

UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE
著者:: Alistair J. Roddick, 等
出版事項: (2023-10-01)

Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors
著者:: Herrington, WG, 等
出版事項: (2021)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
著者:: Herrington, WG, 等
出版事項: (2023)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
著者:: Staplin, N, 等
出版事項: (2016)

Evidence for the prevention and treatment of stroke in dialysis patients
著者:: Herrington, W, 等
出版事項: (2014)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
著者:: Herrington, W, 等
出版事項: (2018)

Conventional and genetic evidence on the association between adiposity and CKD
著者:: Zhu, P, 等
出版事項: (2020)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
著者:: Lamprea-Montealegre, J, 等
出版事項: (2019)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
著者:: Zhu, P, 等
出版事項: (2020)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
著者:: Haynes, R, 等
出版事項: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
著者:: Haynes, R, 等
出版事項: (2014)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
著者:: Storey, B, 等
出版事項: (2017)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
著者:: Zhu, P, 等
出版事項: (2020)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
著者:: Mihaylova, B, 等
出版事項: (2019)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
著者:: Herrington, W, 等
出版事項: (2014)

Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD
著者:: Fletcher, RA, 等
出版事項: (2024)

Impact of CKD on household income
著者:: Morton, R, 等
出版事項: (2017)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
著者:: Herrington, W, 等
出版事項: (2016)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
著者:: Haynes, R, 等
出版事項: (2018)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
著者:: Storey, B, 等
出版事項: (2018)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
著者:: Staplin, N, 等
出版事項: (2015)

Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study
著者:: Donovan, K, 等
出版事項: (2022)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
著者:: Reith, C, 等
出版事項: (2017)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
著者:: Staplin, N, 等
出版事項: (2022)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
著者:: Schlackow, I, 等
出版事項: (2017)

Angiotensin receptor blockers and β-blockers in Marfan syndrome: an individual-patient-data meta-analysis of randomised trials
著者:: Pitcher, A, 等
出版事項: (2022)

Kidney disease trials for the 21st century: innovations in design and conduct
著者:: Herrington, W, 等
出版事項: (2019)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
著者:: C. Reith, 等
出版事項: (2017-05-01)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
著者:: Emberson, J, 等
出版事項: (2016)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
著者:: Cholesterol Treatment Trialists' Collaboration, 等
出版事項: (2016)

Use of gel-based separator tubes to stabilise phosphate in mailed blood samples.
著者:: Herrington, W, 等
出版事項: (2015)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
著者:: Mafham, M, 等
出版事項: (2017)

Benefits of lowering cholesterol in chronic kidney disease Reply
著者:: Baigent, C, 等
出版事項: (2011)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
著者:: Mayne, KM, 等
出版事項: (2024)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
著者:: Mayne, K, 等
出版事項: (2024)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
著者:: Mayne, K, 等
出版事項: (2023)

The authors reply
著者:: Chapman, D, 等
出版事項: (2023)